Author Archives: yaoyan 姚艳

Going Nuclear: The Boom of Radiopharmaceutical Targets in 2024

In 2024, the radiopharmaceutical sector has seen a flurry of activity in mergers and acquisitions. In March, AstraZeneca announced a $2.4 billion acquisition of Fusion Pharmaceuticals, a biopharmaceutical company focused on developing next-generation radiolabeled conjugates (RDCs). In April, Novartis invested nearly $2.71 billion to partner with PeptiDream to co-develop several macrocyclic-targeted conjugate radiopharmaceuticals. In May, Novartis made […]

Blog 2024-10-18
The structure of CD74

CD73: A Potential Target in Cancer Immunotherapy

On September 25, 2024, I-Mab announced a strategic collaboration with Sanofi to develop, produce, and commercialize uliledlimab in Greater China. This partnership, valued at approximately €213 million (around 1.7 billion RMB), aims to leverage Sanofi’s expertise in oncology to accelerate the development and commercialization of uliledlimab, which is an innovative CD73 monoclonal antibody independently developed […]

Blog 2024-10-09
the structural changes and activation of ERBB-HER receptors

HER3/ERBB3: Dominating Cancer Therapy with ADCs and Beyond

On September 17, a collaboration between Daiichi Sankyo and Merck announced that patritumab deruxtecan, a potentially first-in-class antibody-drug conjugate (ADC) targeting HER3, has met its primary endpoint for progression-free survival (PFS) in the Phase 3 lung cancer trial HERTHENA-Lung02. This treatment demonstrated statistically significant improvement compared to platinum-based chemotherapy combined with pemetrexed induction and pemetrexed […]

Blog 2024-09-27
Immunobiology of systemic lupus erythematosus

Who Dominates the Billion-Dollar Market for Systemic Lupus Erythematosus Treatment?

According to a blog released by market intelligence provider Future Market Insights, Inc. (FMI) on September 12 this year, the global market for systemic lupus erythematosus (SLE) drugs is showing significant growth, with surprising acceleration. FMI predicts that the SLE drug market will experience robust expansion in the coming years. In 2020, the market was […]

Blog 2024-09-25
The pathophysiological process of MM and BCMA signaling pathway

Research Progress on BCMA-Targeted Therapies in Multiple Myeloma

On August 27, 2024, Legend Biotech’s BCMA CAR-T product, Carvykti® (generic name: ciltacabtagene autoleucel injection), received approval from the National Medical Products Administration (NMPA) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). Previously, under Johnson & Johnson’s leadership, Carvykti had already been introduced in the United States, the European Union, […]

Blog 2024-09-12
The gene location and protein structure of TRPV1

TRPV1: An Important Target for Pain Treatment

Do you remember the temperature and touch receptor TRPV1 that made American scientists David Julius and Ardem Patapoutian accessible to the Nobel Prize in Physiology or Medicine in 2021? Transient Receptor Potential Vanilloid 1 (TRPV1) has gained significant attention in the field of pain treatment due to its potential as a therapeutic target. However, as […]

Blog , 2024-09-11

MC4R: A Niche Target in the Weight Loss Drug Market

On July 16, 2024, Dr. Roger Cone, co-founder of the preclinical biotech company Courage, published a study in The Journal of Clinical Investigation titled “Subthreshold activation of the melanocortin system causes generalized sensitization to anorectic agents in mice.” The research demonstrated the synergistic effect between GLP-1 receptor agonists (GLP1RA) and MC4R agonists, revealing that low […]

Blog , 2024-09-02
the structure of BCMA

Research Progress on Targeting BCMA in Autoimmune Diseases

The B cell maturation antigen (BCMA), a target that gained prominence due to its association with multiple myeloma, has recently shown significant progress in the treatment of autoimmune diseases. On May 10, 2024, a research team led by Wang Wei from the Department of Neurology at Tongji Hospital, Tongji Medical College, Huazhong University of Science […]

Blog , 2024-08-26
the structure of GPL1R

GLP1R Target: Not Just for Blood Sugar Control and Weight Loss, but a Potential Breakthrough for Anti-Nausea in Weight Loss Medications

Currently, the most popular GLP1-based monotherapy, Semaglutide, controls blood sugar by promoting insulin secretion and induces a lasting sense of fullness to reduce appetite. However, this drug can cause side effects such as nausea and vomiting, which can affect patient adherence to the treatment. On July 10, 2024, Kuei-Pin Huang and colleagues published a paper […]

Blog , 2024-08-19
The structure of GIPR

GIP Receptor (GIPR): A Novel Target for Glycemic Control and Weight Loss

On February 27, 2024, Viking Therapeutics announced the results of their Phase IIa clinical study for VK2735, a dual GLP-1R/GIPR agonist for obesity. The results showed a maximum weight loss of 13.1% after 13 weeks of treatment. Following this news, Viking’s stock surged by 121%. The company has received written feedback from the FDA and […]

Blog , 2024-08-08